Exhibition of antifungal resistance by sterol-auxotrophic strains of *Candida glabrata* with intact virulence

Minoru Nagi1,2, Koichi Tanabe3,4*, Kazuko Tanaka3, Keigo Ueno1, Hironobu Nakayama5, Jun Ishikawa1, Masahiro Abe1, Satoshi Yamagoe4, Takashi Umeyma1, Shigeki Nakamura6, Motoyuki Sugai2, Kevin C. Hazen7 and Yoshitsugu Miyazaki1

1Department of Fungal Infection, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan; 2Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan; 3Department of Food Science and Human Nutrition, Faculty of Agriculture, Ryukoku University, 1-5 Yokotani, Seta Oe-cho, Otsu, Shiga 520-2194, Japan; 4Research Center for Fermentation and Brewing, Ryukoku University, 1-5 Yokotani, Seta Oe-cho, Otsu, Shiga 520-2194, Japan; 5Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3 Minami-Tamagaki, Suzuka, Mie 513-8670, Japan; 6Department of Microbiology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan; 7Department of Pathology, Duke University Health System, 2902 DUMC, 116 CARL Building, Durham, NC 27710, USA

*Corresponding author. E-mail: ktanabe@agr.ryukoku.ac.jp

Received 6 October 2021; accepted 7 February 2022

**Background:** *Candida glabrata* is an emerging fungal pathogen in immune-compromised hosts. Previously undetected *C. glabrata* isolates were successfully recovered from clinical specimens by adding sterols to the growth medium. The clinical isolates are unable to synthesize ergosterol but can take up exogenous sterols under aerobic conditions.

**Objectives:** This study characterizes the sterol-auxotrophic *C. glabrata* strains, examines the mutation(s) in sterol synthesis genes, characterizes the drug susceptibility and evaluates the virulence in a mouse infection model.

**Methods:** Drug susceptibility of the *C. glabrata* strains was evaluated in a sterol-supplemented medium. The coding sequences of the sterol synthesis genes were analysed in six sterol-auxotrophic strains of *C. glabrata*. The fungal burden of mice infected with *C. glabrata* strain was determined.

**Results:** The sterol-auxotrophic strains showed high-level resistance to both azoles and amphotericin B when sterols were supplied in the test medium. Additionally, the strains harbour missense mutations in either *ERG1* or *ERG7*. Significant differences in fungal burden were not observed between the sterol-auxotrophic strain and the sterol-competent strain with the mice infection models.

**Conclusions:** The sterol-auxotrophic *C. glabrata* strain investigated in this study seemed to maintain intact virulence, probably due to the supply of exogenous sterols from host organ(s). This suggests that exogenous sterol uptake develops antifungal resistance during infection.

**Introduction**

The most common species that causes candidiasis has been *Candida albicans*. An emerging trend of a shift toward infections with non-albicans *Candida* species has been observed in candidiasis. Consequently, *Candida glabrata* has increased as an agent of bloodstream infection, especially within ICUs of some hospitals. The presence of *C. glabrata* as an aetiological agent presents with some challenges in patient management because of its potentially reduced susceptibility toazole antifungals. In a global surveillance study, approximately 18.3% of all *C. glabrata* clinical isolates were found to be fluconazole resistant (MIC of >64 mg/L). *C. glabrata* strains that are unable to synthesize ergosterol have been isolated from the urinary tract, indicating that endogenous ergosterol synthesis of *C. glabrata* could be omitted inside the host tissues. The most probable hypothesis is that exogenous sterol uptake can replace endogenous ergosterol synthesis for the growth of *C. glabrata* during an infection.

*C. glabrata* closely resembles *Saccharomyces cerevisiae* compared with other *Candida* spp. in several of its features.
S. cerevisiae can accumulate exogenous sterol under anaerobic or aerobic conditions when harbouring specific mutations. Anaerobic sterol uptake has also been observed in C. glabrata, and it has been estimated that similar sterol uptake mechanisms are conserved between these genetically close relatives. Our past studies have demonstrated that a sterol transporter (AusI), two transcription factors (Upc2A and Upc2B), and a putative mannoprotein (Tir3) are responsible for sterol uptake in yeast. The mutant C. glabrata, which lacks AUS1, exhibited reduced virulence in mouse infection experiments. We also showed that the serum, as an exogenous sterol source, promoted both exogenous sterol uptake and the growth of C. glabrata cells, wherein endogenous sterol synthesis was inhibited byazole treatment. These observations strongly suggest that sterol uptake plays a significant role in the infection and azole resistance of C. glabrata.

Herein, we characterized the antifungal susceptibility, sterol uptake activity and virulence of sterol-auxotrophic clinical isolates of C. glabrata. In addition, the expression levels of the genes responsible for sterol uptake and the sequences of ergosterol synthesis genes were also determined with these strains. These results altogether indicate that endogenous sterol synthesis in C. glabrata cells is unnecessary during an infection. The sterol uptake activity of C. glabrata induces tolerance to azoles during antifungal chemotherapy.

Materials and methods

Ethics

All animal experiment protocols complied with the guidelines and policies of the Principles of Morality for Animal Experiments of the National Institute of Infectious Disease, Japan (approval number 111073).

Strains and media

The C. glabrata strains used in this study are listed in Table 1. Yeasts were grown in yeast extract–peptone–dextrose (YPD) medium [1% Bacto yeast extract (Difco), 2% Bacto-peptone (Difco) and 2% glucose] containing 0.5% Tween 80-ethanol [1:1 (vol/vol)], and 20 mg/L sterols were supplied if indicated. Solid media were supplemented with 2% agar (Nacalai Tesque, Kyoto, Japan). The following compounds, ergosterol, ergosterol acetate and ergosterol propionate, were purchased from FUJIFILM Wako Pure Chemical Corporation, LTD, Osaka, Japan. Lathosterol and β-sitosterol were obtained from Nagara Science Co. Ltd, Gifu, Japan and TAMA Biochemical Co. Ltd, Tokyo, Japan, respectively.

| Strain | Description | References |
|--------|-------------|------------|
| CBS138 | Reference strain | CBS |
| L999a | Bile-independent clinical isolate | Hazen et al. (2005) |
| 73246 | Bile-dependent clinical isolate | Hazen et al. (2005) |
| S53452 | Bile-dependent clinical isolate | Hazen et al. (2005) |
| H32441 | Bile-dependent clinical isolate | Hazen et al. (2005) |
| M34736 | Bile-dependent clinical isolate | Hazen et al. (2005) |
| W16119 | Bile-dependent clinical isolate | Hazen et al. (2005) |

*aPutative parental strain of 73246.

The rest used for growth supplementation were obtained from Sigma–Aldrich. The growth rescue of sterol-auxotrophic isolates was evaluated by the streak plate assay. Each strain was streaked on the YPD agar medium containing 20 mg/L sterols and incubated at 37°C for 24 h. In this study, 20 mg/L of any sterol was enough to support the growth of the sterol-auxotrophic isolates either on agar medium or in liquid medium.

Quantification of sterols by HPLC

Ergosterol, cholesterol or lanosterol uptake was detected by reverse-phase HPLC as described before. The mean values and standard deviation of triplicate measurements from a representative experiment are shown.

Antifungal susceptibility

Approximately 2 × 10⁵ cells were used to inoculate YPD medium (200 μL) and were then cultured with serially diluted fluconazole (from 0 to 1024 mg/L; Pfizer), or amphotericin B (from 0 to 64 mg/L; Sigma–Aldrich Chemical Co., St Louis, MO, USA). After incubation at 37°C for 24 h, the OD at 595 nm of the culture was measured to determine antifungal susceptibility using a Beckman Coulter DTX880 Multimode Detector (Fullerton, CA, USA). No significant growth of C. glabrata cells was observed in RPMI1640.

Semi-quantitative RT-PCR

Cells grown in YPD medium containing 20 mg/L cholesterol and 0.5% Tween 80-ethanol at 37°C overnight were inoculated at approximately 1 × 10⁶ cells/mL and cultured for 4 h in YPD medium in the presence of 20 mg/L cholesterol and 0.5% Tween 80-ethanol. Total RNA was prepared from the cells and semi-quantitative RT-PCR was performed as described elsewhere except for the following: SuperScript™ VILO™ cDNA Synthesis Kit (Invitrogen) and a Mx3000P PCR System (Agilent Technologies, Santa Clara, CA, USA). All primers used for qRT-PCR are listed in Table S1 (available as Supplementary data at JAC-AMR Online). All experiments were repeated with three independent preparations of RNA, and a representative result was exhibited. The mean fold changes compared with the value of CBS138 and standard deviation of triplicate measurements from a representative experiment are shown.

Sequencing of ergosterol biosynthesis genes

The ergosterol biosynthesis genes of the sterol-auxotrophic C. glabrata isolates other than 73246 were determined by Sanger sequencing. The cells were grown in a 1.5 mL YPD medium containing 20 mg/L cholesterol and 0.5% Tween 80-ethanol at 30°C overnight. Genomic DNA was isolated from an overnight culture using the Dr. GenTLE (from yeast) High Recovery kit (Takara-Bio, Otsu, Japan). The high-fidelity Phusion DNA polymerase (New England Biolabs Japan) was used for amplification. The PCR conditions involved 35 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 10 s and extension at 72°C for 120 s. Purification of PCR fragments was performed by ExoSAP-IT™ PCR Product Cleanup (Life Technologies Corporation, Carlsbad, CA, USA) following the manufacturer’s instructions. The sequences of all amplified DNA fragments were determined using the BigDye Terminator v.3.1 Cycle Sequencing Kit (Life Technologies, Tokyo, Japan) and analysed using the 3730xl DNA Analyzer (Life Technologies) by a customized service (Premix sequence, Takara-bio). The primers for amplification and sequencing are listed in Table S1.

As to the 73246 alone, next-generation sequencing was performed using the Illumina paired-end technology. The trimmed reads were assembled with the Velvet 1.2.10. Mapping of the reads to a reference sequence was performed with BWA 0.7.17 and variant calling was performed with Platypus 0.8.1.1.
Animal studies

The fungal tissue burden and expression analysis were performed as described previously.16 Five male BALB/c mice aged 7 weeks (Japan SLC Inc.) were used for a group. To establish C. glabrata infection, mice were injected into their tail vein with saline suspensions of $1 \times 10^7$ viable cells (in a volume of 200 μL). After 7 days, mice were sacrificed by CO2 inhalation, and target organs (kidney and spleen) were excised aseptically, individually weighed and homogenized in sterile saline using a 70 μm Cell strainer (BD Falcon, Franklin Lakes, NJ, USA). Organ homogenates were diluted and plated onto YPD containing streptomycin sulphate salt (Sigma–Aldrich), penicillin G sodium salt (Sigma–Aldrich), 20 mg/L cholesterol and 0.5% Tween 80-ethanol. Colonies were counted after 1 day of incubation at 37°C and the numbers of cfu/g of the organ were calculated. Statistical analyses were conducted using GraphPad Prism6™ via an unpaired t-test with a significance level of $P, 0.05$.

Results

Exogenously supplied sterols were aerobically taken up in the sterol-auxotrophic strains

The growth of these strains on YPD agar plates in various sterols and squalene, an intermediate compound in the sterol synthesis pathway, were examined (Figure 1). Cholesterol or ergosterol supported the growth of sterol-auxotrophic strains under aerobic conditions, as previously reported (Figure 1b and c). The taken-up sterols were detected in the strains, and the amounts of those in the cells except 73246 and S53452 were roughly comparable to ergosterol ($\sim 2500$ ng/OD600 unit) in the sterol-competent strains, CBS138 or L999 (Figure 2, Table S2). The amount of taken-up ergosterol in 73246 and S53452 was 41.3% (1025 ± 43 ng/OD600 unit) and 23.4% (582 ± 14 ng/OD600 unit) of that in the sterol-competent L999. The amount of taken-up total cholesterol in the strains ranged from 1301 (M34736) to 2335 (73246) ng/OD600 unit. These suggest that ergosterol, the final product of yeast sterol synthesis or alternative cholesterol directly compensates for the ergosterol shortage in the clinical isolates of C. glabrata cells. Exogenously supplied sterols were reported to be esterified immediately after being incorporated in S. cerevisiae.17 The comparison between the total (sum of esterified- and free-sterols) and free revealed that both ergosterol and cholesterol were retained as free form (Table S2).

Lanosterol also supported the growth of the mutants except for W16119 (Figure 1d). Two of them (S53452 and H32441) showed complete growth restoration with lanosterol, whereas
the other two (73246 and M34736) exhibited only partial growth restoration (Figure 1d). A significant amount of ergosterol was detected in the strains with growth restoration by lanosterol (Figure 2c, Table S2). These results indicate that taken-up lanosterol was converted into ergosterol in these strains.

Additionally, to major sterols, 17 commercially available sterols and sterol esters were evaluated for rescuing the growth of sterol-auxotrophic strains (Table 2). Ten compounds (group A) could support the growth of all tested \textit{C. glabrata} strains. 25-Hydroxycholesterol was unable to support the growth of any strain. The results of six of the compounds (group B) partially supported the growth depending on the strain.

\textbf{Exogenously supplied sterols affect the drug susceptibilities of the sterol-auxotrophic strains}

Exogenous sterol also affected the drug susceptibility of the sterol-auxotrophic cells (Table 3). The strains exhibited extremely high MIC (more than 1024 mg/L, the maximum concentration in this assay) of fluconazole in the presence of any sterols that were categorized group A (Table 3).

The addition of cholesterol but not ergosterol increased the MIC of amphotericin B (Table 4). The sterol-mediated alteration of antifungal susceptibility was not observed in the sterol-competent strains. These results indicated that exogenous sterol was aerobically taken up, and it is sorted to the plasma membrane in the sterol-auxotrophic strains.

\textbf{Aerobic upregulation of sterol uptake genes in the sterol-auxotrophic strains}

We had previously demonstrated that both \textit{AUS1} and \textit{TIR3} (which encode an ATP-binding cassette transporter and a mannoprotein, respectively) are indispensable for sterol uptake in \textit{C. glabrata}.

The expression level of the genes was kept low in sterol-competent \textit{C. glabrata} cells under aerobic normal growth conditions, whereas the depletion of oxygen or iron resulted in highly enhanced expression of the genes. The expression level of the sterol uptake genes, \textit{AUS1} or \textit{TIR3}, was significantly upregulated in the sterol-auxotrophic strains under aerobic growth conditions (Figure 3). The expression level of \textit{AUS1} or \textit{TIR3} in sterol-auxotrophic mutants was at least 20- or 150-fold of those in CBS138, respectively.
Table 2. The growth profile of the sterol-deficient clinical isolates of *C. glabrata* in the presence of various sterols or sterol-related compounds

| Supplements (20 mg/L)            | 73246 | SS3452 | H32441 | M34736 | W16119 |
|----------------------------------|-------|--------|--------|--------|--------|
| Ergosterol                       | +     | +      | +      | +      | +      |
| Lanosterol                       | +     | +      | +      | +      | −      |
| Lathosterol                      | +     | +      | +      | +      | −      |
| 7-Dehydrocholesterol             | +     | +      | +      | +      | +      |
| Ergosterol acetate               | +     | +      | +      | +      | +      |
| Ergosterol propionate            | +     | +      | +      | −      | +      |
| 25-Hydroxycholesterol            | −     | −      | −      | −      | −      |
| Cholesterol                      | +     | +      | +      | +      | +      |
| Stigmasterol                     | −     | +      | +      | −      | −      |
| β-Sitosterol                     | −     | +      | +      | −      | −      |
| Campesterol                      | +     | +      | +      | −      | +      |
| Desmosterol                      | +     | +      | +      | +      | −      |
| Brassicasterol                   | +     | +      | +      | +      | +      |
| Fucosterol                       | −     | −      | +      | −      | −      |
| β-Cholesterol                    | +     | +      | +      | +      | +      |
| Stigmasterol                     | +     | +      | +      | +      | +      |
| Cholesteryl acetate              | +     | +      | +      | −      | −      |

+, visible growth in streak test with YPD medium supplemented by indicated compound; −, no growth in streak test with YPD medium supplemented by indicated compound.

(Figure 3a and b). These suggest that the two genes responsible for sterol uptake were unusually upregulated under aerobic conditions and made the mutant cells aerobically take up exogenous sterols. The expression of ATP-binding cassette transporter genes, *CDR1* or *PDH1*, which were responsible for enhanced azole resistance, was not significantly upregulated in the sterol-auxotrophic mutants (Figure 3c and d). These results also suggest that enhanced azole resistance in the presence of exogenous sterol was not caused by drug efflux by Cdr1p or Pdh1p (Table 3).

**Sterol-auxotrophic strains harbour mutation(s) in sterol synthesis genes**

Sterol profiles of the sterol-auxotrophic *C. glabrata* strains indicated that two of them (W16119 and M34736) were defective in lanosterol synthase (encoded by the *ERG7* gene), whereas the other two (H32441 and SS3452) were defective in squalene epoxidase (encoded by the *ERG1* gene). However, a missense mutation was also detected in *ERG7* of the 73246 genome by next-generation sequencing. To further assess the mutation(s) in the series of sterol synthesis genes, 21 coding region DNA sequence (CDS) of the genes were determined (Table 5). The CDSs of W16119 and M34736 were identical, H32441 and SS3452 were also observed to be identical (Table 5). Both W16119 and M34736 shared identical mutations in seven genes (*ERG2*, *ERG7*, *ERG8*, *ERG9*, *ERG10*, *HMG1* and *MVD1*). In contrast, H32441 and SS3452 have identical mutations in nine genes (*ERG1*, *ERG2*, *ERG4*, *ERG6*, *ERG7*, *ERG8*, *ERG10*, *ERG24* and *MVD1*). Of all mutations detected, the insertion of five nucleotides (TCGCT) in the *ERG1* gene results in a substitution of amino acid residue and stop codon (I16R followed by a stop codon ‘TAG’) (Table 5). Another single nucleotide deletion in the *ERG7* gene results in Y321T and N322I followed by a stop codon ‘TGA’. The nonsense mutation in *ERG1* or *ERG7* was thought to disrupt the function of the enzyme coded by each gene, whereas the effect from other mutations, which cause amino acid substitutions on the sterol synthesis enzymes, was unclear.

**The sterol-auxotrophic *C. glabrata* strains retain intact virulence in a mouse model of disseminated infection**

The effect of sterol deficiency during disseminated infection was tested in a mouse infection model. Mice were inoculated IV with the sterol-auxotrophic 73246 and its putative parental sterol-competent strain, L999. In mice infected with 73246, the number of cells recovered from spleen was about 28 times higher than that from mice infected with L999 (Figure 4a). However, the cell numbers recovered from the kidney when infected with the two strains were not significantly different from each other (Figure 4b). These results indicate that the defect in ergosterol does not reduce the infection efficacy of *C. glabrata*.

**Discussion**

In this study, we evaluated the sterol uptake activity, drug susceptibility and virulence of the sterol-auxotrophic clinical isolates of *C. glabrata*. Our results suggested that the deficiency in sterol synthesis does not attenuate the survival of *C. glabrata* cells inside host bodies. This may be an unacceptable idea for most researchers as sterol synthesis is indispensable for any fungal cells in vitro. It was possible that the number of sterol-auxotrophic *C. glabrata* strains inside host tissues was small and that the strains were accidentally isolated under limited clinical situations. These strains were isolated from limited types of specimen (mainly from
Table 3. The fluconazole susceptibility of the sterol-deficient clinical isolates of *C. glabrata* in the presence of various sterols or sterol-related compounds

| Supplements (20 mg/L)                        | CBS138 | L999 | 73246 | SS3452 | H32441 | M34736 | W16119 |
|----------------------------------------------|--------|------|-------|--------|--------|--------|--------|
| Tween 80 and ethanol (vehicle)               | 128    | 16   | ND    | ND     | ND     | ND     | ND     |
| Ergosterol                                   | 128    | 32   | >1024  | >1024  | >1024  | >1024  | >1024  |
| Lanosterol                                   | 128    | 16   | >1024  | >1024  | >1024  | >1024  | >1024  |
| Lathosterol                                  | 128    | 16   | >1024  | >1024  | >1024  | >1024  | >1024  |
| 7-Dehydrocholesterol                         | 128    | 32   | >1024  | >1024  | >1024  | >1024  | >1024  |
| Ergosterol acetate                           | 128    | 16   | >1024  | >1024  | >1024  | >1024  | >1024  |
| Ergosterol propionate                         | 128    | 16   | >1024  | >1024  | ND     | ND     | >1024  |
| 25-Hydroxycholesterol                        | 128    | 16   | ND    | ND     | ND     | ND     | ND     |
| Cholesterol                                  | 128    | 16   | >1024  | >1024  | >1024  | >1024  | >1024  |
| Stigmasterol                                  | 128    | 16   | ND    | ND     | ND     | ND     | ND     |
| β-Sitosterol                                  | 128    | 16   | >1024  | >1024  | >1024  | >1024  | >1024  |
| Campesterol                                  | 128    | 16   | >1024  | >1024  | >1024  | >1024  | >1024  |
| Desmosterol                                  | 128    | 16   | >1024  | >1024  | >1024  | >1024  | >1024  |
| Brassicasterol                                | 128    | 16   | >1024  | >1024  | >1024  | >1024  | >1024  |
| Fucosterol                                   | 128    | 16   | ND    | ND     | ND     | ND     | ND     |
| β-Cholestanol                                | 128    | 16   | >1024  | >1024  | >1024  | >1024  | >1024  |
| Stigmastanol                                 | 128    | 16   | >1024  | >1024  | >1024  | >1024  | >1024  |
| Cholesteryl acetate                          | 128    | 16   | >1024  | >1024  | ND     | ND     | >1024  |

ND, not determined due to poor or no growth in liquid medium.

Table 4. The amphotericin B susceptibility of the sterol-deficient clinical isolates of *C. glabrata* in the presence of various sterols or sterol-related compounds

| Supplements (20 mg/L)                        | CBS138 | L999 | 73246 | SS3452 | H32441 | M34736 | W16119 |
|----------------------------------------------|--------|------|-------|--------|--------|--------|--------|
| No reagent                                   | 0.5    | 0.25 | ND    | ND     | ND     | ND     | ND     |
| Tween 80 and ethanol (vehicle)               | 8      | 4    | ND    | ND     | ND     | ND     | ND     |
| Ergosterol                                   | 4      | 2    | 1     | 2      | 2      | 2      | 0.5    |
| Lanosterol                                   | 16     | 8    | 8     | 8      | 8      | 8      | ND     |
| Lathosterol                                  | 8      | 4    | 4     | 4      | 4      | 4      | 4      |
| 7-Dehydrocholesterol                         | 4      | 2    | 2     | 8      | 4      | 4      | 4      |
| Ergosterol acetate                           | 8      | 4    | 2     | 8      | ND     | ND     | 2      |
| Ergosterol propionate                         | 8      | 4    | 2     | 8      | ND     | ND     | 2      |
| 25-Hydroxycholesterol                        | 4      | 2    | ND    | ND     | ND     | ND     | ND     |
| Cholesterol                                  | 8      | 4    | 16    | >64    | 16     | >64    | 16     |
| Stigmasterol                                  | 4      | 2    | ND    | 8      | 16     | ND     | ND     |
| β-Sitosterol                                  | 8      | 4    | ND    | 16     | 32     | 16     | ND     |
| Campesterol                                  | 8      | 4    | 16    | 32     | 16     | >64    | 16     |
| Desmosterol                                  | 8      | 8    | 16    | 16     | 16     | 16     | 16     |
| Brassicasterol                                | 4      | 2    | 4     | 16     | 8      | 16     | 16     |
| Fucosterol                                   | 8      | 4    | ND    | 16     | ND     | ND     | 16     |
| β-Cholestanol                                | 8      | 4    | 16    | 16     | 32     | 16     | 4      |
| Stigmastanol                                 | 8      | 2    | 8     | 32     | 64     | >64    | 8      |
| Cholesteryl acetate                          | 8      | 4    | 16    | >64    | ND     | ND     | 64     |

ND, not determined due to poor or no growth in liquid medium.
However, in continuous surveillance over a 1 month period, 10.8% of the isolates derived from the urine required bile, the source of externally supplied sterol, for growth. Another trial of isolation of sterol-deficient *C. glabrata* strains revealed that some bile-dependent strains were isolated from the nasopharynx or blood. These accumulated data of clinical isolates indicated that a certain ratio of yeast cells, most of which were *C. glabrata*, exhibited sterol auxotrophy. In yeast, oxygen is required for multiple sterol biosynthesis reactions. Sterol synthesis in *C. glabrata* cells during infections is expected to be restricted as the dissolved molecular oxygen levels are low in some parts of the organs. We demonstrated that the mutant *C. glabrata* strain, which lacked the exogenous sterol uptake (*aus1Δ*), exhibited decreased fungal burden in the mouse infection models. These observations suggest that sterol uptake in *C. glabrata* cells is necessary to obtain enough sterols to grow during infection, and partly illustrate the intact virulence of the sterol-auxotrophic clinical isolates due to the supplementation of exogenous sterols from the host body.

The analysis of cellular sterols in this study revealed that most incorporated sterols in the sterol-auxotrophic strains were retained in the free form, and that the limited ratio of the sterols was esterified (Table S2). The taken-up exogenous sterols were esterified and stored in the lipid particle in *S. cerevisiae*. The only desirable sterols for growth among the esterified sterols were sorted to the plasma membrane or supplied for the endogenous ergosterol synthesis pathway. The taken-up sterols are also esterified in *C. glabrata* and sorted to plasma membranes as in the case of *S. cerevisiae*.

The amount of total ergosterol in 73246 and S53452 was half or a quarter of the sterol-competent strain, respectively, when ergosterol was exogenously supplied (Figure 2a, Table S2). The growth restoration by ergosterol was comparable to the other sterol-auxotrophic mutants (Figure 1b). These observations suggest that the amount of ergosterol, which probably resides in plasma membranes, did not significantly affect the growth ratio or the physiological membrane property of *C. glabrata* cells, at least within the values for ergosterol detected in this study. The

**Figure 3.** Expression of genes related to either sterol uptake or drug resistance in the sterol-auxotrophic *C. glabrata* strains under aerobic conditions. Total RNA was extracted from aerobically grown *C. glabrata* cells in the presence of 20 mg/L cholesterol. The expression of the genes was evaluated using quantitative RT-PCR analysis with the extracted total RNA. The expression of each gene in the cells is shown as a relative fold change normalized to the expression in CBS138 cells using Livak’s ΔΔCt method. Values are means and standard deviations of triplicate measurements from a representative experiment. (a) *AUS1*, (b) *TIR3*, (c) *CDR1* and (d) *PDH1*.
sequencing of ergosterol synthesis genes showed that 73246 and S53452 harbour missense mutations in ERG7 and ERG1, respectively (Table 5). This also indicates that the ergosterol synthesis block point does not correlate with the sterol uptake activities.

The growth restoration by lanosterol, an intermediate compound of the sterol synthesis pathway, was poor in 73246 or M34736 (Figure 1d). The amount of total ergosterol, converted from taken-up lanosterol, in these strains (985 ± 10 and 482 ± 20 in 73246 and M34736, respectively) was also slightly smaller than those in other strains (Table S2). This suggests that about 1000 ng/OD600 unit of total ergosterol would be required for the intact growth of C. glabrata cells. W16119, which harbours a missense mutation in ERG7 identical to 73246 or M34736, did not show growth restoration by supplementation with lanosterol, whereas similar growth restoration was observed by supplementation with ergosterol or cholesterol (Figure 1b and c). This indicates that W16119 could take up exogenous sterol similar to other strains but had additional mutations in gene(s) other than the missense mutation in ERG7, which critically inhibit the conversion of lanosterol to ergosterol. It was also notable that the strain H32441, which harbours a missense mutation in ERG1, accumulated a significant amount of squalene. This result did not contradict the previous report that ERG1-deleted S. cerevisiae mutant accumulate 4-fold the amount of squalene of the WT strain.18 SS3452 did not show squalene accumulation, however the strain also had a mutated ERG1 CDS identical to H32441 (Table 5). These results suggest that additional mutation(s) in some genes related to sterol metabolism in SS3452 resulted in little squalene accumulation in the strain.

Of 17 commercially available sterol or sterol-related compounds, 10 compounds could support the growth of sterol-auxotrophic clinical isolates of C. glabrata. These compounds (group A) were thought to be taken up as efficiently as ergosterol and replaceable with ergosterol at the plasma membrane, as they supported the growth of W16119, which cannot convert lanosterol to ergosterol. It is hard to predict the structural moieties required for the growth supplementation of strains, as there is no clear correlation between the sterols' structural moieties and growth supplementation. 25-Hydroxycholesterol may not be incorporated into C. glabrata cells like other steroidal compounds for unknown reasons or because it is not converted into some functional sterols by C. glabrata.

The drug susceptibility of the C. glabrata strains reflected the sterol uptake properties of the cells. The MIC of the tested strains for fluconazole was more than the maximum concentration (1024 mg/L) in the presence of any tested sterol-related compounds (Table 3). Fluconazole inhibits the fungal lanosterol 14α-demethylase and inhibits ergosterol synthesis. It was expected that most of the sterol-related compounds taken up

### Table 5. Mutation(s) detected in the genes responsible for ergosterol synthesis of the sterol-deficient clinical isolates of C. glabrata

| Gene name | W16119 | M34736 | H32441 | SS3452 | 73246 | L999 |
|-----------|--------|--------|--------|--------|-------|------|
| ERG1      |        |        | missense a | missense a |      |      |
| ERG2      | 1207V  | 1207V  | 1207V  | 1207V  | 1207V | 1207V |
| ERG3      | T13N   | T13N   |        |        |      |      |
| ERG4      |        |        |        |        |      |      |
| ERG5      |        |        |        |        |      |      |
| ERG6      |        |        |        |        |      |      |
| ERG7      | missense b | missense b | R48K  | R48K  |      |      |
| ERG8      | N448S  | N448S  | T732A  | T732A  |      |      |
| ERG9      | C344Y  | C344Y  | N448S  | N448S  |      |      |
| ERG10     | N170D  | N170D  | N170D  | N170D  |      |      |
| ERG11     |        |        |        |        |      |      |
| ERG12     |        |        |        |        |      |      |
| ERG13     |        |        |        |        |      |      |
| ERG14     |        |        |        |        |      |      |
| ERG15     |        |        |        |        |      |      |
| ERG16     |        |        |        |        |      |      |
| ERG17     |        |        |        |        |      |      |
| ERG18     |        |        |        |        |      |      |
| ERG19     |        |        |        |        |      |      |
| ERG20     |        |        |        |        |      |      |
| ERG21     |        |        |        |        |      |      |
| ERG22     |        |        |        |        |      |      |
| ERG23     |        |        |        |        |      |      |
| ERG24     |        |        |        |        |      |      |
| ERG25     |        |        |        |        |      |      |
| ERG26     |        |        |        |        |      |      |
| ERG27     |        |        |        |        |      |      |
| HMG1      | S92L, K140Q, D775N, G1028A | S92L, K140Q, D775N, G1028A | G1028A, K140Q, D775N | G1028A, K140Q, D775N |      |      |
| MVD1      | K65N, S70A | K65N, S70A | S70A | S70A |      |      |
| IDI1      |        |        |        |        |      |      |

---

aMissense by insertion (TCGCT) at 45 (15LIV → 15LRI*).
bMissense (T961del) (321YNL → 321TI*).
cMissense (C1121del) (374PQGM → HKV*).
exogenously by the *C. glabrata* cells directly became the alternative to ergosterol in the plasma membrane to salvage the growth inhibition by fluconazole. However, it was intriguing to observe that the supplementation with lanosterol also abolished the growth inhibition by fluconazole. The incorporated lanosterol will not be converted into ergosterol in the presence of fluconazole. It was shown that *C. glabrata* cells accumulate an unusual sterol (**4,14-demethylzymosterol**) when treated with fluconazole, whereas other fungal species accumulate a toxic sterol intermediate in the presence of fluconazole.11,19 The characteristic response to fluconazole in *C. glabrata* cells might have enabled the conversion of the supplemented lanosterol to a non-toxic alternative sterol. The MIC of the strains for amphotericin B was intriguing. Amphotericin B is thought to permeabilize the plasma membranes by binding to ergosterol of fungal cells.20,21

The MIC of the sterol-auxotrophic mutants for amphotericin B was as much as that of the sterol-competent strains when exogenous ergosterol was supplied (Table 4). Our result suggests that the incorporated ergosterol was sorted to the plasma membrane in the sterol-auxotrophic mutants, and that the major sterol in the plasma membranes was ergosterol. These significant changes in drug susceptibility caused by sterol uptake may partly illustrate the tolerance of *C. glabrata* cells for the drugs targeting ergosterol synthesis during infections.

In the mice infection models, the sterol-auxotrophic strain 73246 exhibited a fungal burden in kidney comparable to that of the putative parental strain L999 (Figure 4b). This suggests that *C. glabrata* cells obtained enough sterol, probably cholesterol from host organs during infections. Interestingly, about 28 times more *C. glabrata* cells were recovered from the spleen in 73246-infected mice when compared with mice infected with sterol-competent L999 (Figure 4a). This further indicates the possibility that auxotrophy for sterol offers a tissue-specific survival advantage to *C. glabrata* cells in some tissues. However, more experiments with other sterol-auxotrophic strains should be conducted to make such a proposition. It is also suggested that a mouse mortality model or *Galleria mellonella* larval model will give a clear answer to the role of sterol uptake in virulence.

The results in this study and previous reports demonstrated the significance of sterol uptake of *C. glabrata* cells in both virulence and drug susceptibility inside host tissues. More attention should be paid to this characteristic activity of *C. glabrata* under clinical situations.

**Acknowledgements**

We are grateful to Ms Satsuki Okamoto for intensive laboratory work.

**Funding**

This research was partly supported by AMED under Grant Number JP21fk0108135h0902 (to K.T.).

**Transparency declarations**

None to declare.

**Supplementary data**

Tables S1 and S2 are available as Supplementary data at JAC-AMR Online.

**References**

1 Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. *Lancet Infect Dis* 2011; 11: 142–51.
2 Hazen KC, Baron EJ, Colombo AL et al. Comparison of the susceptibilities of *Candida* spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. *J Clin Microbial* 2003; 41: 5623–32.

---

**Figure 4.** The virulence of sterol-deficient *C. glabrata* with a mouse infection model. Fungal tissue burdens in kidneys (a) and spleen (b) from groups of five BALB/c mice infected via the tail vein with $1 \times 10^7$ viable cells of the *C. glabrata* strains. Mice were sacrificed at Day 7 post-infection. Results are expressed as cfu/g of tissue and represent values recorded separately for each of the five mice. Geometric means are indicated by horizontal bars. Statistical comparisons are summarized above each panel. Asterisks indicate statistically significant differences (*P* < 0.05; **P** < 0.01). NS indicates no significance (*P* > 0.05).
3 Pfaffer MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: 1366–77.

4 Bard M, Sturm AM, Pierson CA et al. Sterol uptake in Candida glabrata: rescue of sterol auxotrophic strains. Diagn Microbiol Infect Dis 2005; 52: 285–93.

5 Hazen KC, Stei J, Darracott C et al. Isolation of cholesterol-dependent Candida glabrata from clinical specimens. Diagn Microbiol Infect Dis 2005; 52: 35–7.

6 Nagi M, Tanabe K, Ueno K et al. The Candida glabrata sterol scavenging mechanism, mediated by the ATP-binding cassette transporter Aus1p, is regulated by iron limitation. Mol Microbiol 2013; 88: 371–81.

7 Nakayama H, Tanabe K, Bard M et al. The Candida glabrata putative sterol transporter gene CgAZU1 regulates ergosterol biosynthetic genes in Candida glabrata. Genes Cells 2011; 16: 80–9.

8 Inukai T, Nagi M, Morita A et al. The mannoprotein TIR3 (CAGL0C03872 g) is required for sterol uptake in Candida glabrata. Biochim Biophys Acta 2015; 1851: 141–51.

9 Ta MT, Kapterian TS, Fei W et al. Accumulation of squalene is associated with the clustering of lipid droplets. FEBS J 2012; 279: 4231–44.

10 Kelly SL, Lamb DC, Corran AJ et al. Mode of action and resistance toazole antifungals associated with the formation of 14α-methylergosta-8,24(28)-dien-3β,6α-diol. Biochem Biophys Res Commun 1995; 207: 910–5.

11 Yamamoto T, Urmegawa Y, Tsuchikawa H et al. The amphothericin B-ergosterol complex spans a lipid bilayer as a single-length assembly. Biochemistry 2019; 58: 5188–96.

12 Grela E, Zdybicka-Barabas A, Pawlikowska-Pawlega B et al. Modes of the antibiotic activity of amphotericin B against Candida albicans. Sci Rep 2019; 9: 17029.